Alterity Therapeutics (ASX:ATH) Share Price and News

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Expand Company Description

Market Cap (10-Oct) $15,736,981 (1,258th)	Close (30-Jun) $0.007 0 (0%)	Volume (30-Jun) 188,484	Shortsold (23-Sep) 1,628,842 (0.03%) (488th)
52w High $0.008	52w Low $0.002	P/E -	EPS -0.01

	Subject
	ATH ATH Ann: Investor Presentation
	1 (current) 2 3
	ATH ATH Ann: ATH to present at MST Rare Diseases Rich Returns Forum
	ATH ATH Ann: ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
	ATH ATH Ann: First Patient Enrolled in Australia in global Phase 2 Trial
	ATH ATH Ann: Appendix 4C and Quarterly Cash Flow Report
	ATH ATH Ann: bioMUSE Wearable Sensor Data presented at AAN Annual Meeting
	ATH ATH Ann: Notification of cessation of securities - ATH
	ATH ATH Ann: First Patient Enrolled in UK in Phase II Clinical Trial
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: Notice Under Section 708A
	ATH ATH Ann: Application for quotation of securities - ATH
	ATH ATH Ann: First Patient Enrolled in USA in Phase II Clinical Trial
	ATH ATH Ann: Proposed issue of securities - ATH
	ATH ATH Ann: US patent grant and license agreement
	ATH ATH Ann: Investor Webinar Presentation
	ATH ATH Ann: First Patient Enrolled in Europe in Phase II Clinical trial
	ATH ATH Ann: Half Yearly Report and Accounts
	ATH ATH Ann: Regulatory approval for Phase II trial in France and Austria
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: Notification of cessation of securities - ATH
	ATH ATH Ann: Appendix 4C and Quarterly Cash Flow Report
	ATH ATH Ann: ATH434 Prevents Brain Cell loss in Parkinsons Animal Model
	ATH ATH Ann: ATH434 Clinical Trial Launched in Italy
	ATH ATH Ann: ATH434 clinical trial launched in the US
	ATH ATH Ann: ADS ratio change
	ATH ATH Ann: Alterity to participate in Sachs Neuroscience Conference
	ATH ATH Ann: New US patent for compounds to treat neurodegeneration
	ATH ATH Ann: Change of Director's Interest Notice x 4
	ATH ATH Ann: Notification of cessation of securities - ATH
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: ATH Constitution (amended)
	ATH ATH Ann: Results of Annual General Meeting
	ATH ATH Ann: Chairman's Address 2022 Annual General Meeting
	ATH ATH Ann: ATH Annual General Meeting Presentation
	ATH ATH Ann: Presentation of bioMUSE urinary symptom profile data
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: Appendix 4C and Quarterly Cash Flow Report
	ATH ATH Ann: Presentation of bioMUSE MRI data
	ATH ATH Ann: ATH434 Clinical Trial launched in Australia
	ATH ATH Ann: Notice of Annual General Meeting/Proxy Form
	ATH ATH Ann: Change in substantial holding
	ATH ATH Ann: Wearable Sensor Data from bioMUSE Natural History Study
	ATH ATH Ann: Notice Under Section 708A
	ATH ATH Ann: Application for quotation of securities - ATH
	ATH ATH Ann: Proposed issue of securities - ATH
	ATH ATH Ann: US FDA Approval for IND Application for ATH434 for MSA
	ATH ATH Ann: Alterity Form 20-F and XBRL data filed with SEC
	ATH ATH Ann: Appendix 4G and Corporate Governance Statement 2022
	ATH ATH Ann: Appendix 4E & Annual Report 2022

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
10-Oct	$0.00	3,625	0.00 (25.00%)
09-Oct	$0.00	12,936	+0.00 (33.33%)
08-Oct	$0.00	226,076	0.00 (25.00%)
07-Oct	$0.00	2,155,755	+0.00 (33.33%)
04-Oct	$0.00	10,000	0.00 (0.00%)
03-Oct	$0.00	10,832,351	0.00 (25.00%)
02-Oct	$0.00	3,191,180	0.00 (0.00%)
01-Oct	$0.00	1,269,390	+0.00 (33.33%)
30-Sep	$0.00	2,273,213	0.00 (0.00%)
12-Sep	$0.00	7,373,231	0.00 (0.00%)
11-Sep	$0.00	150,000	0.00 (0.00%)
10-Sep	$0.00	66,666	0.00 (0.00%)
09-Sep	$0.00	104,457	0.00 (0.00%)
06-Sep	$0.00	12,828,484	0.00 (0.00%)
05-Sep	$0.00	61,564,393	0.00 (14.29%)
3 up, 4 down, and 8 flat days

High $0.01	Low $0.01	Trades 19	Turnover $1,131	Volume 188,484
30 June 2023 at 4:10pm

High $0.01	Low $0.01	Trades 19	Turnover $1,131	Volume 188,484
30 June 2023 at 4:10pm

Alterity Therapeutics Health Care

$0.007 0.001 (16.67%)

$0.007 0.001 (16.67%)

Followers

Prices

Announcements

Similar Companies

End of Day Prices